Clinical Trials Directory

Trials / Unknown

UnknownNCT05414370

Hyperoxia Induced Pulmonary Inflammation and Organ Injury: a Human in Vivo Model

Effects of Hyperoxia Induced Pulmonary Inflammation and Organ Injury in a Human in Vivo Model

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
53 (estimated)
Sponsor
Belfast Health and Social Care Trust · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Oxygen is the most commonly administered therapy in critical illness. Accumulating evidence suggests that patients often achieve supra-physiological levels of oxygenation in the critical care environment. Furthermore, hyperoxia related complications following cardiac arrest, myocardial infarction and stroke have also been reported. The underlying mechanisms of hyperoxia mediated injury remain poorly understood and there are currently no human in vivo studies exploring the relationship between hyperoxia and direct pulmonary injury and inflammation as well as distant organ injury. The current trial is a mechanistic study designed to evaluate the effects of prolonged administration of high-flow oxygen (hyperoxia) on pulmonary and systemic inflammation. The study is a randomised, double-blind, placebo-controlled trial of high-flow nasal oxygen therapy versus matching placebo (synthetic medical air). We will also incorporate a model of acute lung injury induced by inhaled endotoxin (LPS) in healthy human volunteers. Healthy volunteers will undergo bronchoalveolar lavage (BAL) at 6 hours post-intervention to enable measurement of pulmonary and systemic markers of inflammation, oxidative stress and cellular injury.

Conditions

Interventions

TypeNameDescription
DRUGLiquid oxygenLiquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
DRUGmedical airSynthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.

Timeline

Start date
2022-12-02
Primary completion
2024-12-30
Completion
2024-12-30
First posted
2022-06-10
Last updated
2024-01-29

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05414370. Inclusion in this directory is not an endorsement.